TLR2 and respiratory tract infectious disorder: Our results are in line with studies reporting that mucosal vaccines with synthetic TLR2 ligand adjuvants and respiratory infections with Gram-positive bacteria elicited strong Th17, but not Th1 or Th2, responses (26, 27).